Here, we report suboptimal efavirenz exposure in an obese patient treated with the standard 600 mg dose. Tripling the dose allowed attainment of therapeutic efavirenz concentrations. We developed an in vitro–in vivo extrapolation model to quantify dose requirements in obese individuals. Obesity represents a risk factor for antiretroviral therapy underdosing.
References
1.
Crum-CianfloneN., Poehlman RoedigerM., EberlyL.Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS ONE2010; 5: e10106.
2.
MossD.M., KwanW.S., LiptrottN.J.Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother2011; 55: 879–887.
3.
PoulinP., TheilF.P.Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci2002; 91: 129–156.
4.
WardB.A., GorskiJ.C., JonesD.R., HallS.D., FlockhartD.A., DestaZ.The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther2003; 306: 287–300.
5.
OgburnE.T., JonesD.R., MastersA.R., XuC., GuoY., DestaZ.Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos2010; 38: 1218–1229.
6.
BélangerA.S., CaronP., HarveyM., ZimmermanP.A., MehlotraR.K., GuillemetteC.Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos2009; 37: 1793–1796.
7.
LangT., KleinK., FischerJ.Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics2001; 11: 399–415.
8.
NCBI.dbSNP short genetic variations (Updated 19 March 2012. Accessed 12 April 2012.) Available from www.ncbi.nlm.nih.gov/SNP.
9.
MarzoliniC., TelentiA., DecosterdL.A., GreubG., BiollazJ., BuclinT.Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS2001; 15: 71–75.
10.
ColomboS., BeguinA., TelentiA.Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci2005; 819: 259–276.
11.
FayetA., BeguinA., de TejadaB.M.Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit2008; 30: 511–522.
12.
StöhrW., BackD., DunnD.Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther2008; 13: 675–685.
13.
Sustiva (efavirenz).Package insert2004. Bristol–Myers SquibbPrinceton, NJ, USA.
14.
JainR., ChungS.M., JainL.Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther2011; 90: 77–89.
15.
JullienV., TréluyerJ.M., ReyE.Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother2005; 49: 3361–3366.
